Lung Cancer Clinical Trials

Showing 2401-2420 of 4,288 trials

Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer

NCT05320458

The aim of our study is to investigate the effects of pulmonary rehabilitation on respiratory tests and quality of life in patients with early and locally advanced NSCLC who received chemotherapy regardless of whether the investigators had undergone surgical treatment.

Lung CancerLung Cancer, Small Cell

Hasan Kalyoncu University11 participantsStarted May 2022

Gaziantep, Turkey (Türkiye)

COMPLETEDPhase 1

A Study of LY3023414 in Participants With Advanced Cancer

NCT01655225

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.

Advanced CancerMetastatic CancerNon-Hodgkin's Lymphoma+3 more

Eli Lilly and Company156 participantsStarted Jul 2012

Los Angeles, California, United States • New York, New York, United States • Oklahoma City, Oklahoma, United States +5 more locations

Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer

A Study of LY3023414 in Participants With Advanced Cancer

Related Searches

Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Utility of LDCT in Lung Cancer Screening in a TB Endemic Region

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Gefitinib Long-term Survivor Study

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

MRD Monitoring in Lung Cancer After Resection

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)